BioViva Secures Two U.S. Patents for Longevity Gene Therapies Targeting Klotho, hTERT and Follistatin-344
核心洞察
BioViva USA received U.S. Patent No. 12,564,646 covering Klotho (搜索) and hTERT gene therapy delivered via AAV8 (搜索) and AAV9 (搜索) vectors for age-related cognitive decline (搜索).
A second patent, No. 12,653,907, protects combined hTERT and Follistatin-344 (搜索) gene therapy aimed at telomere maintenance, muscle mass and blood-glucose levels.
Both patents were issued by the USPTO in 2026, with European Union and China applications for the Klotho (搜索) patent still pending examination.
BioViva USA, Inc. (搜索) has secured two U.S. patents covering gene therapy approaches directed at the biological mechanisms of aging, one targeting age-related cognitive decline (搜索) and another combining two longevity-associated genes for age-related disorders.
The Bainbridge Island, Washington-based biotechnology company announced U.S. Patent No. 12,564,646, titled "Treatment of Age-Related Cognitive Decline (搜索) Using Genetically Modified Viral Vectors," issued by the United States Patent and Trademark Office (搜索) on March 3, 2026. The patent covers the use of gene therapy to deliver human Klotho (搜索) (KL) and telomerase reverse transcriptase (hTERT) for the treatment or prevention of age-related cognitive decline, including conditions associated with dementia (搜索) and Alzheimer's disease (搜索).
According to the company, the patent describes multiple gene-delivery approaches, including several viral-vector platforms and different routes of administration. The issued claims specifically include the use of AAV8 (搜索) and AAV9 (搜索) vectors delivered intranasally to provide Klotho (搜索) and hTERT.
Klotho (搜索) is a naturally occurring protein that has been associated with healthy aging and neurological function. BioViva's patent focuses on using gene therapy to enable cells to produce Klotho, rather than simply administering the protein itself.
"This patent is an important milestone for BioViva and for the broader effort to address the biology underlying age-related disease," said Elizabeth Parrish, CEO of BioViva USA, Inc. (搜索) "Klotho (搜索) has emerged as one of the most interesting genes associated with healthy aging. Our goal is to develop therapies that address the underlying biological mechanisms of aging rather than simply treating the diseases that emerge later in life."
Patent protection for the Klotho (搜索) and hTERT technology in the European Union and China is currently pending, extending BioViva's intellectual property strategy into two additional international markets. The company said it expects additional patent decisions as these applications proceed through their respective examination processes.
Dual-Gene Patent Combines hTERT and Follistatin-344
In a second announcement, BioViva disclosed the issuance of U.S. Patent No. 12,653,907, titled "Methods of Treating or Preventing Age-Related Disorders," covering therapeutic methods involving the combination of hTERT and Follistatin-344 (搜索) (FST). The patent was issued by the USPTO on June 16, 2026, with BioViva USA Inc. as assignee.
The patented technology combines two biological targets with complementary roles in aging biology. hTERT, the catalytic component of telomerase, is involved in telomere maintenance; telomeres protect the ends of chromosomes and are associated with cellular replicative capacity and aging. Follistatin-344 (搜索), encoded by the FST gene, is a protein involved in biological pathways associated with muscle and tissue function.
The patent covers methods in which hTERT and Follistatin-344 (搜索) are administered in combination for the treatment or prevention of age-related disorders. The issued claims include approaches associated with telomere length, muscle mass and blood-glucose levels, and the patent also encompasses genetic delivery approaches including the use of viral vectors such as adeno-associated virus (AAV).
"This patent represents an important milestone in BioViva's effort to develop a new category of medicine focused on the biology of aging," Parrish said. "We have been working for years to develop genetic approaches that address fundamental mechanisms associated with aging. Protecting the combination of hTERT and Follistatin-344 (搜索) strengthens our ability to advance that work."
An Intellectual-Property Strategy Built Around Aging Biology
BioViva has pursued an intellectual-property strategy focused on targeting biological mechanisms associated with aging rather than addressing each age-related disease as an isolated condition. The company's research and intellectual-property portfolio include programs involving telomere maintenance, tissue and muscle biology, metabolic regulation and cognitive decline.
"Aging is the greatest risk factor for many of the diseases that ultimately limit human healthspan," Parrish said. "Our goal is to move medicine upstream, to address the biology that contributes to age-related decline rather than simply treating its consequences one disease at a time."
The company said the issuance of the patents strengthens its intellectual property portfolio and creates opportunities for further research, licensing, development and potential partnerships involving its gene therapy approaches. Pending applications in additional jurisdictions could further expand the geographic scope of its intellectual property protection.
Investigational Status and Regulatory Caveats
BioViva emphasized that the issuance of a patent does not establish the safety or efficacy of a therapeutic product or guarantee regulatory approval. The company's investigational approaches remain subject to applicable regulatory requirements and clinical development, including preclinical and clinical requirements. Pending patent applications in the European Union, China and other jurisdictions may not result in issued patents or may result in claims of different scope.
BioViva USA Inc. describes itself as a biotechnology company developing genetic therapies intended to address biological mechanisms associated with aging and age-related disease, with research programs spanning telomere maintenance, tissue regeneration, metabolic pathways and cognitive function. The company's stated mission is to advance genetic and regenerative technologies with the potential to extend healthy human lifespan and address diseases associated with biological aging.